Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Recruiting · NCT00903110
Conditions: IGF1 Deficiency
At a glance
- Research payments reported, 2025
- $15,407
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 500
About the trial
- Sponsor
- Esteve Pharmaceuticals, S.A.
- Tested
- Increlex® (drug)
- Dates
- Started 2008-12-09; completion 2027-12-31
- Results posted
- Not yet
The Increlex® Global Registry is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The main purpose of this global registry is to collect, analyse and report safety data during and up to at least 5 years after the end of treatment in children and adolescents receiving Increlex® therapy for SPIGFD according to the locally approved product information.
From ClinicalTrials.gov, last updated 2026-02-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Pharma Sas reported $15,407 in research payments for this study in 2025 (5 payments).
Products named: Increlex
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amrit Bhangoo, MD Pediatric Endocrinology · Long Beach, CA
- Iris Gutmark-little, M.D. Pediatric Endocrinology · Cincinnati, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.